Generic Eptus ( Eplerenone )

Buy Generic Eptus (Eplerenone) without prescription in Canada

Eptus is a brand name for eplerenone used in some international markets. In Canada, eplerenone is marketed as Inspra and by several generic manufacturers. This article provides comprehensive patient information about eplerenone 25 mg, including its uses, dosing, safety, and practical guidance for Canadian patients.

Eptus (Eplerenone 25 mg): Comprehensive Patient Information for Canada

Basic Product Information

Mechanism of Action

In simple terms: Eptus is a selective aldosterone blocker. Aldosterone is a hormone in your body that can cause fluid retention and put stress on your heart. By blocking aldosterone, this medicine helps reduce fluid buildup and protects your heart from damage. It works by blocking the effects of aldosterone on mineralocorticoid receptors in the kidneys, heart, and blood vessels.

For specialists: Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone system. Aldosterone synthesis occurs primarily in the adrenal gland and is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial tissues, such as the kidney, and nonepithelial tissues, such as the heart, blood vessels, and brain. It increases blood pressure through induction of sodium reabsorption and possibly other mechanisms. Eplerenone selectively binds to human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone, and androgen receptors. This selectivity distinguishes eplerenone from spironolactone, which binds less selectively and is associated with antiandrogenic side effects such as gynecomastia.

Pharmacokinetics

• Absorption: Eplerenone is rapidly absorbed after oral administration. Mean peak plasma concentrations are reached approximately 1.5 to 2 hours following oral administration. The absolute bioavailability is 69% following administration of a 100 mg oral tablet. Absorption is not affected by food. Both peak plasma levels and area under the curve are dose proportional for doses of 25 mg to 100 mg and less than proportional at doses above 100 mg.
• Metabolism: Eplerenone is cleared predominantly by cytochrome P450 3A4 metabolism. No active metabolites of eplerenone have been identified in human plasma.
• Distribution: The plasma protein binding of eplerenone is approximately 50%, and it is primarily bound to alpha 1-acid glycoproteins. The apparent volume of distribution at steady state ranged from 42 to 90 L.
• Elimination: The elimination half-life of eplerenone is approximately 3 to 6 hours. The apparent plasma clearance is approximately 10 L/hr. Less than 5% of an eplerenone dose is recovered as unchanged drug in the urine and feces. Following a single oral dose of radiolabeled drug, approximately 32% of the dose was excreted in the feces and approximately 67% was excreted in the urine.
• Onset of Action: Steady-state levels are reached within 2 days upon repeat dosing. The therapeutic benefit in heart failure is achieved over weeks to months of consistent use.
• Duration of Action: The elimination half-life of 3 to 6 hours supports once- or twice-daily dosing, depending on the indication.

Uses in Daily Life and Best Practice Advice

Eplerenone is prescribed in Canada as an adjunct to standard therapy for specific cardiovascular conditions. Your physician will determine the appropriate use and dose based on your specific medical situation.

• Typical Uses: Inspra is indicated as an adjunct to standard therapy to reduce the risk of cardiovascular mortality and hospitalization for heart failure in patients with NYHA class II systolic chronic heart failure and left ventricular systolic dysfunction. It is also indicated to reduce the risk of mortality and hospitalization for heart failure following myocardial infarction in clinically stable adult patients with evidence of heart failure and left ventricular systolic dysfunction with ejection fraction of 40% or less. Additionally, it is indicated for the treatment of mild and moderate essential hypertension, usually in combination with other drugs, for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate.
• Administration: Take the tablet orally, with or without food. Swallow the tablet whole. The dose is usually taken once or twice daily, depending on the indication and your response to treatment.
• Monitoring: Serum potassium level should be measured and glomerular filtration rate should be estimated before starting eplerenone therapy. Eplerenone should not be administered if initial serum potassium is greater than 5.0 mmol/L or if estimated glomerular filtration rate is less than 30 mL/min/1.73 m². Regular monitoring of potassium levels and kidney function is essential during treatment.
• Do Not Stop Without Medical Advice: Do not stop taking eplerenone without consulting your physician, as this may worsen your heart condition.

Morning vs. Evening Dosing

Eplerenone is typically taken once or twice daily. There is no specific clinical recommendation for morning versus evening dosing. Taking it at the same time each day helps maintain consistent blood levels. Always follow the schedule recommended by your physician.

• Once Daily or Twice Daily: The dosing frequency depends on the indication. For heart failure, it is often taken once daily. For hypertension, it may be taken once or twice daily.
• Consistency: Take eplerenone at the same times each day to ensure consistent effects.
• Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time.
• Professional Guidance: Your healthcare provider may adjust the timing based on your response to treatment.

Administration With or Without Food

Eplerenone can be taken with or without food. Absorption is not affected by food. This flexibility makes it convenient to take at any time of day.

• Swallow the tablet whole with a full glass of water.
• Eplerenone can be taken with or without food.
• Do not crush or chew the tablet.
• Avoid drinking grapefruit juice while taking eplerenone, as it may increase the levels of eplerenone in your blood.
• Avoid potassium supplements or salt substitutes containing potassium unless directed by your physician, as eplerenone can increase potassium levels.

Interaction Warnings

Indications for Eplerenone

"Off-label" means use outside the official approved indication, usually based on current medical guidelines and scientific evidence.

Dosing According to Clinical Indication

Doses should always be adjusted according to the advice of your physician and depending on your health condition, kidney function, and serum potassium levels. Do not exceed the recommended dose unless advised by a physician.

Side Effects and Safety Profile

Guidelines for Correct Use

• Take eplerenone exactly as prescribed by your physician. Do not change your dose without medical advice.
• Swallow the tablet whole with a full glass of water, with or without food, at the same times each day.
• Have your serum potassium and kidney function checked before starting eplerenone and regularly during treatment.
• Do not use potassium supplements or salt substitutes containing potassium unless directed by your physician.
• Avoid drinking grapefruit juice while taking eplerenone.
• Do not stop taking this medication without consulting your physician.
• Inform every healthcare provider, including dentists, surgeons, and pharmacists, that you are taking eplerenone.
• If you are pregnant, planning to become pregnant, or breastfeeding, consult your physician before use.
• If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double the dose.
• Store at room temperature, between 15 and 30 degrees Celsius, in a dry place. Keep out of reach of children.

Alternative Treatment Options

• Spironolactone (Aldactone): A non-selective mineralocorticoid receptor antagonist. It is also effective for heart failure and hypertension. However, it is associated with a higher incidence of antiandrogenic side effects such as gynecomastia, breast tenderness, and menstrual irregularities compared with eplerenone. It is significantly less expensive than eplerenone.
• Finerenone (Kerendia): A newer non-steroidal mineralocorticoid receptor antagonist. It is indicated for chronic kidney disease associated with type 2 diabetes. It is not currently indicated for heart failure in Canada.
• Angiotensin-Converting Enzyme Inhibitors (e.g., ramipril, enalapril): These are standard therapies for heart failure and hypertension. They work by reducing the production of angiotensin II, which in turn reduces aldosterone levels.
• Angiotensin Receptor Blockers (e.g., losartan, valsartan): Alternative RAAS inhibitors for patients who cannot tolerate ACE inhibitors.
• Beta-Blockers (e.g., bisoprolol, carvedilol): Standard therapy for heart failure with reduced ejection fraction.

Comparison: Eplerenone is distinguished from spironolactone by its greater selectivity for the mineralocorticoid receptor, which results in fewer antiandrogenic side effects such as gynecomastia and breast tenderness. However, eplerenone is significantly more expensive than spironolactone. Both agents carry a risk of hyperkalemia and require monitoring of potassium and kidney function. The Canadian Cardiovascular Society guidelines recommend eplerenone and spironolactone as evidence-based mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction. Eplerenone is not listed on the British Columbia drug formulary, while spironolactone has universal coverage across Canada. Your physician will determine the best option for your specific condition, taking into account your medical history, kidney function, and financial considerations.

Legal Status, Registration, and Coverage in Canada

• Registration: Eplerenone is authorized for sale in Canada by Health Canada as a prescription drug. Inspra (BGP Pharma ULC) is available in 25 mg and 50 mg tablets. Generic formulations include Jamp Eplerenone 25 mg and 50 mg, and Mint-Eplerenone 25 mg and 50 mg. Apo-Eplerenone 25 mg has also been approved.
• Prescription Status: Prescription only in Canada.
• Coverage: Coverage varies by province and territory. In Alberta, eplerenone is listed under Special Authorization on the Alberta Drug Benefit List, with a unit price of $1.3730 per tablet for generic products and $3.3373 for the brand. In Ontario, eplerenone is available as an Off-Formulary Interchangeable product with a drug benefit price of $1.3730 per tablet. In Quebec, eplerenone is covered as an exceptional medication under the RAMQ formulary, with a monthly treatment cost of approximately $75, compared with less than $2 per month for spironolactone. Eplerenone is not listed on the British Columbia drug formulary. Generic formulations are generally more affordable than the brand-name product.
• Pharmacovigilance: Adverse reactions should be reported to Health Canada's MedEffect Canada program.

Recent Research and Clinical Guidelines (2022–2026)

• The Canadian Cardiovascular Society 2025 guidelines list spironolactone and eplerenone as evidence-based mineralocorticoid receptor antagonist options for heart failure with reduced ejection fraction. The guidelines explicitly do not include finerenone for this indication.
• The EPHESUS trial randomized 6,632 patients and demonstrated that the risk of death with eplerenone was reduced by 15% compared with placebo.
• The EMPHASIS-HF trial showed that eplerenone added to recommended therapy for systolic heart failure in patients with mild symptoms was associated with a reduction in the rate of death from a cardiovascular cause or hospitalization for heart failure. In this trial, patients received eplerenone 25 mg daily, increasing to 50 mg daily after four weeks, or matching placebo.
• Recent analyses from the EPHESUS trial found that in the placebo group, higher baseline aldosterone or an increase over one month was associated with cardiovascular death or heart failure hospitalization, whereas these associations were not observed in the eplerenone group.
• The SCARF-1 trial is an ongoing open-label pilot trial evaluating the feasibility, safety, and efficacy of eplerenone in patients with heart failure with reduced ejection fraction and severe chronic kidney disease.
• Research continues to explore the role of eplerenone in various clinical settings, including its use in patients with heart failure with preserved ejection fraction, although this remains an off-label indication.

Availability and Supply in Canada

Prices and availability may vary by province, territory, and pharmacy. Generic eplerenone formulations are available in Canada and are generally more affordable than the brand-name product. In Quebec, the monthly treatment cost with eplerenone is approximately $75, compared with less than $2 per month for spironolactone. Check with your local pharmacy for current pricing and availability.

Frequently Asked Questions (FAQ)

1. What is Eptus, eplerenone, used for?
   Eptus is used to treat high blood pressure and to reduce the risk of death and hospitalization in patients with heart failure after a heart attack or with mild chronic heart failure.
2. How does eplerenone work?
   Eplerenone works by blocking the effects of aldosterone, a hormone that can cause fluid retention and put stress on your heart. By blocking aldosterone, it helps reduce fluid buildup and protects your heart from damage.
3. What is the correct dose of eplerenone?
   The usual starting dose for heart failure is 25 mg once daily, which may be increased to 50 mg once daily after 4 weeks if your potassium levels are acceptable. For hypertension, the usual dose is 50 mg once daily, which may be increased to 100 mg once daily. Your physician will determine the appropriate dose for your condition.
4. Can I take eplerenone with food?
   Yes. Eplerenone can be taken with or without food. Food does not affect the absorption of the medication.
5. What should I do if I miss a dose?
   If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time.
6. Can I drink alcohol while taking eplerenone?
   No. Alcohol should not be consumed while taking eplerenone because it may worsen heart conditions and increase the risk of low blood pressure.
7. What are the serious side effects of eplerenone?
   Serious side effects include hyperkalemia, which is high potassium levels and can cause irregular heartbeat and muscle weakness, kidney problems, and severe allergic reactions. Seek immediate medical attention if you experience muscle weakness, irregular heartbeat, or signs of a severe allergic reaction.
8. Is eplerenone safe during pregnancy?
   Eplerenone should be used during pregnancy only if clearly needed. There are no adequate data on its use in pregnant women. Consult your physician if you are pregnant or planning to become pregnant.
9. Is eplerenone safe during breastfeeding?
   It is unknown if eplerenone is excreted in human breast milk. A decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Consult your physician before use.
10. Are there alternatives to eplerenone?
    Yes. Alternatives include spironolactone, another mineralocorticoid receptor antagonist, ACE inhibitors, ARBs, and beta-blockers. Spironolactone is significantly less expensive than eplerenone but is associated with a higher incidence of antiandrogenic side effects such as gynecomastia. Your physician will determine the best option for your specific condition.
11. Is eplerenone covered by Canadian health insurance?
    Coverage varies by province and territory. In Alberta, eplerenone is listed under Special Authorization. In Ontario, it is available as an Off-Formulary Interchangeable product. In Quebec, it is covered as an exceptional medication. Eplerenone is not listed on the British Columbia drug formulary. Check with your provincial drug plan and private insurance provider for coverage details.